FDA Drug Recalls

Recalls / Class II

Class IID-0390-2023

Product

Finasteride Tablets USP, 1 mg, Rx Only, Packaged as: a) 30-count bottle NDC 16729-089-10 UPC 3 16729 08910 4; b) 90-count bottle NDC 16729-089-15 UPC 3 16729 08915 9; Manufactured for: Accord Healthcare, Inc., Durham, NC 27703. Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213 INDIA

Brand name
Finasteride
Generic name
Finasteride
Active ingredient
Finasteride
Route
Oral
NDC
16729-089
FDA application
ANDA091643
Affected lot / code info
Batches: a) P2005979, Exp. Date 10/31/2023; P2100252, Exp. Date 12/31/2023; P2101710, Exp. Date 2/29/2024; b) P2100253, Exp. Date 12/31/2023; P2103035, Exp. Date 4/30/2024; P2103036, Exp. Date 4/30/2024;

Why it was recalled

CGMP Deviations: recalling drug products following an FDA inspection.

Recalling firm

Firm
Accord Healthcare, Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
1009 Slater Rd Ste 210B, N/A, Durham, North Carolina 27703-8446

Distribution

Quantity
325,356 bottles
Distribution pattern
United States including Puerto Rico and Canada

Timeline

Recall initiated
2023-02-07
FDA classified
2023-03-02
Posted by FDA
2023-03-08
Terminated
2024-04-22
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0390-2023. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.